CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus

Journal of Autoimmunity

Volumn 63, Issue , 2015, Pages 59-67

  Clement, Marc ^a   Charles, Nicolas ^b,c   Escoubet, Brigitte ^d   Guedj, Kevin ^a   Chauveheid, Marie Paule ^d   Caligiuri, Giuseppina ^a,c   Nicoletti, Antonino ^a,c   Papo, Thomas ^b,c,d   Sacre, Karim ^b,c,d  

^a Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^b CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Accelerated atherosclerosis; Chemokines; CXCR3+CD4+ T cells; Lupus; Plasmacytoid dendritic cells

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN E; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; TOLL LIKE RECEPTOR 9; CXCR3 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD LEVEL; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IN VITRO STUDY; INTERNAL CAROTID ARTERY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; COMPLICATION; DENDRITIC CELL; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, KNOCKOUT; MODELS, IMMUNOLOGICAL; RECEPTORS, CXCR3;

EID: 84940848113     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.07.001     Document Type: Article

References (50)

1. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger T.A., Jansen-McWilliams L., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 1997, 145:408-415.
2. Esdaile J.M., Abrahamowicz M., Grodzicky T., Li Y., Panaritis C., du Berger R., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthr. Rheumatol. 2001, 44:2331-2337.
3. Roman M.J., Shanker B.A., Davis A., Lockshin M.D., Sammaritano L., Simantov R., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 2003, 349:2399-2406.
4. Asanuma Y., Oeser A., Shintani A.K., Turner E., Olsen N., Fazio S., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 2003, 349:2407-2415.
5. Sacre K., Escoubet B., Pasquet B., Chauveheid M.P., Zennaro M.C., Tubach F., et al. Increased arterial stiffness in systemic lupus erythematosus (SLE) patients at low risk for cardiovascular disease: a cross-sectional controlled study. PLoS One 2014, 9:e94511.
6. Roman M.J., Crow M.K., Lockshin M.D., Devereux R.B., Paget S.A., Sammaritano L., et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthr. Rheumatol. 2007, 56:3412-3419.
7. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 2007, 357:977-986.
8. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Investig. 2005, 115:407-417.
9. Ronnblom L., Alm G.V. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 2001, 194:F59-F63.
10. Doring Y., Manthey H.D., Drechsler M., Lievens D., Megens R.T., Soehnlein O., et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation 2012, 125:1673-1683.
11. Niessner A., Sato K., Chaikof E.L., Colmegna I., Goronzy J.J., Weyand C.M. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006, 114:2482-2489.
12. Goossens P., Gijbels M.J., Zernecke A., Eijgelaar W., Vergouwe M.N., van der Made I., et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metab. 2010, 12:142-153.
13. Somers E.C., Zhao W., Lewis E.E., Wang L., Wing J.J., Sundaram B., et al. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012, 7:e37000.
14. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
15. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Investig. 1999, 104:1041-1050.
16. Kawamura A., Miura S., Fujino M., Nishikawa H., Matsuo Y., Tanigawa H., et al. CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circ. J. 2003, 67:851-854.
17. Fritsch R.D., Shen X., Illei G.G., Yarboro C.H., Prussin C., Hathcock K.S., et al. Abnormal differentiation of memory T cells in systemic lupus erythematosus. Arthr. Rheumatol. 2006, 54:2184-2197.
18. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr. Rheumatol. 1997, 40:1725.
19. Buyon J.P., Petri M.A., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann. Intern. Med. 2005, 142:953-962.
20. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4:295-306.
21. Nicoletti A., Kaveri S., Caligiuri G., Bariety J., Hansson G.K. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J. Clin. Investig. 1998, 102:910-918.
22. Weng Y., Siciliano S.J., Waldburger K.E., Sirotina-Meisher A., Staruch M.J., Daugherty B.L., et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem. 1998, 273:18288-18291.
23. Booth V., Keizer D.W., Kamphuis M.B., Clark-Lewis I., Sykes B.D. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002, 41:10418-10425.
24. Wang Y., Huang Z., Lu H., Lin H., Wang Z., Chen X., et al. Apolipoprotein E-knockout mice show increased titers of serum anti-nuclear and anti-dsDNA antibodies. Biochem. Biophys. Res. Commun. 2012, 423:805-812.
25. Dolff S., Bijl M., Huitema M.G., Limburg P.C., Kallenberg C.G., Abdulahad W.H. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin. Immunol. 2011, 141:197-204.
26. Stanic A.K., Stein C.M., Morgan A.C., Fazio S., Linton M.F., Wakeland E.K., et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7018-7023.
27. Shah K., Lee W.W., Lee S.H., Kim S.H., Kang S.W., Craft J., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthr. Res. Ther. 2010, 12:R53.
28. Zhang Z., Kyttaris V.C., Tsokos G.C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 2009, 183:3160-3169.
29. Taleb S., Tedgui A., Mallat Z. Adaptive T cell immune responses and atherogenesis. Curr. Opin. Pharmacol. 2010, 10:197-202.
30. Gao Q., Jiang Y., Ma T., Zhu F., Gao F., Zhang P., et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J. Immunol. 2010, 185:5820-5827.
31. Zhao Z., Wu Y., Cheng M., Ji Y., Yang X., Liu P., et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis 2011, 217:518-524.
32. Pejnovic N., Vratimos A., Lee S.H., Popadic D., Takeda K., Akira S., et al. Increased atherosclerotic lesions and Th17 in interleukin-18 deficient apolipoprotein E-knockout mice fed high-fat diet. Mol. Immunol. 2009, 47:37-45.
33. Smith E., Prasad K.M., Butcher M., Dobrian A., Kolls J.K., Ley K., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
34. Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 2006, 1:297-329.
35. Laurat E., Poirier B., Tupin E., Caligiuri G., Hansson G.K., Bariety J., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001, 104:197-202.
36. Veillard N.R., Steffens S., Pelli G., Lu B., Kwak B.R., Gerard C., et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005, 112:870-878.
37. Braun N., Wade N.S., Wakeland E.K., Major A.S. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice. Lupus 2008, 17:1070-1078.
38. Wilhelm A.J., Rhoads J.P., Wade N.S., Major A.S. Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice. Ann. Rheum. Dis. 2015, 74:778-785.
39. Ronnblom L., Eloranta M.L., Alm G.V. The type I interferon system in systemic lupus erythematosus. Arthr. Rheumatol. 2006, 54:408-420.
40. Ronnblom L., Alm G.V., Eloranta M.L. The type I interferon system in the development of lupus. Semin. Immunol. 2011, 23:113-121.
41. Thacker S.G., Zhao W., Smith C.K., Luo W., Wang H., Vivekanandan-Giri A., et al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthr. Rheumatol. 2012, 64:2975-2985.
42. Denny M.F., Thacker S., Mehta H., Somers E.C., Dodick T., Barrat F.J., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915.
43. Kaplan M.J. Premature vascular damage in systemic lupus erythematosus. Autoimmunity 2009, 42:580-586.
44. Leonard D., Svenungsson E., Sandling J.K., Berggren O., Jonsen A., Bengtsson C., et al. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ. Cardiovasc. Genet. 2013, 6:255-263.
45. Kahlenberg J.M., Kaplan M.J. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthr. Res. Ther. 2011, 13:203.
46. Niessner A., Weyand C.M. Dendritic cells in atherosclerotic disease. Clin. Immunol. 2010, 134:25-32.
47. Bessant R., Duncan R., Ambler G., Swanton J., Isenberg D.A., Gordon C., et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthr. Rheumatol. 2006, 55:892-899.
48. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthr. Rheumatol. 2010, 62:863-868.
49. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martinez-Berriotxoa A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006, 15:577-583.
50. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthr. Res. Ther. 2012, 14:R155.